GlassScriptPhysician profile
Veronica K Sesi
NPI 1801007620
$1,291.22
in general payments reported to CMS, 2019-2025
15 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $148 · 2021: $262 · 2022: $39.28 · 2023: $217 · 2024: $347 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $691.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $536.16 | 2023-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $227.91 | 2019-2023 | Xywav |
| Harmony Biosciences LLC | $107.63 | 2020-2021 | |
| Emd Serono, INC. | $97.00 | 2019-2020 | |
| Resmed Corp | $63.80 | 2019-2020 | |
| Axsome Therapeutics, INC. | $60.49 | 2023-2025 | Sunosi |
| Biogen, INC. | $48.24 | 2019-2025 | Spinraza |
| Acadia Pharmaceuticals INC | $24.14 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $23.15 | 2025 | Lumryz |
| Novartis Pharmaceuticals Corporation | $21.48 | 2019 | |
| Lilly USA, LLC | $19.98 | 2025 | Zepbound |
| Novo Nordisk INC | $17.97 | 2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $15.14 | 2022 | |
| Mylan Specialty L.P. | $14.22 | 2021 | |
| Electromed, INC. | $13.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Sesi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.